

Isosorbide Dinitrate

Isosorbide dinitrate has been shorted in the past.

A.A. Pharmaceuticals have taken over production from Apotex and it is available again.

Isosorbide dinitrate products listed on Health Canada Drug Product Database:¹

DIN	COMPANY	PRODUCT	CLASS	SCHEDULE#	A.I.NAME	STRENGTH
00670944	AA PHARMA INC	ISDN	HUMAN	1	ISOSORBIDE DINITRATE	5 MG
00441694	AA PHARMA INC	ISDN	HUMAN	1	ISOSORBIDE DINITRATE	30 MG
00441686	AA PHARMA INC	ISDN	HUMAN	1	ISOSORBIDE DINITRATE	10 MG
00786640	PHARMASCIENCE INC.	ISOSORBIDE TAB 30MG	HUMAN	1	ISOSORBIDE DINITRATE	30 MG
00458686	NOVOPHARM LIMITED	NOVO- SORBIDE TAB 10MG	HUMAN	1	ISOSORBIDE DINITRATE	10 MG
00458694	NOVOPHARM LIMITED	NOVO- SORBIDE TAB 30MG	HUMAN	1	ISOSORBIDE DINITRATE	30 MG
00786667	PHARMASCIENCE INC.	PMS- ISOSORBIDE TAB 10MG	HUMAN	1	ISOSORBIDE DINITRATE	10 MG

Therapeutic Uses

Health Canada-approved indications include:

- acute symptomatic relief of angina pectoris and prophylactic management in situations likely to provoke angina attacks
- long-term prophylactic management of stable angina
- perioperative hypertension

Uses Without Health Canada Approval:

- Nitrates are used to treat chest pain during acute coronary syndromes
- the management of acute and chronic heart failure²

Alternatives:

¹ Health Canada Drug Product Database

² Online Compendium of Pharmaceuticals and Specialties

Nitroglycerin : The duration of action of sublingual **isosorbide** dinitrate appears to be longer than that observed with SL nitroglycerin; however, the clinical significance of this difference is questionable.

Isosorbide mononitrate (ISMN) is an active metabolite of the vasodilator **isosorbide** dinitrate. **Isosorbide** mononitrate has been shown to be as or more effective than **isosorbide** dinitrate in the treatment of chronic, stable angina. Other advantages of isosorbide dinitrate are:

- No first pass metabolism
- No active metabolites
- Nearly 100% bioavailable
- Little inter subject variability - evidence that the 20 milligram dose represents optimal therapy for regular release formulation
- Sustained release form allows for once daily dosing increasing acceptability and compliance
- The sustained release tablets may be divided, but should not be chewed or crushed³

Monitoring Parameters:

Blood pressure, heart rate, frequency and severity of anginal attacks, and pulmonary capillary wedge pressure should be monitored to determine therapeutic effectiveness if switching to a different agent.

Also monitor for indications of toxicity such as orthostatic hypotension, syncope, dizziness, palpitations, light-headedness, headache, and blood pressure.

³ DrugDex Evaluations